BidaskClub lowered shares of Neurocrine Biosciences (NASDAQ:NBIX) from a buy rating to a hold rating in a report published on Friday morning, BidAskClub reports.

NBIX has been the subject of a number of other research reports. Zacks Investment Research upgraded Neurocrine Biosciences from a hold rating to a buy rating and set a $97.00 price target for the company in a research report on Wednesday, July 31st. Royal Bank of Canada set a $118.00 price target on Neurocrine Biosciences and gave the company a buy rating in a research report on Friday, September 6th. Needham & Company LLC restated a hold rating on shares of Neurocrine Biosciences in a research report on Wednesday, July 31st. ValuEngine upgraded Neurocrine Biosciences from a hold rating to a buy rating in a research report on Wednesday, July 31st. Finally, Credit Suisse Group raised their price target on Neurocrine Biosciences from $95.00 to $110.00 and gave the company an outperform rating in a research report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Neurocrine Biosciences has an average rating of Buy and a consensus price target of $106.05.

Shares of NBIX stock opened at $97.80 on Friday. Neurocrine Biosciences has a fifty-two week low of $64.72 and a fifty-two week high of $125.59. The stock has a market cap of $8.96 billion, a P/E ratio of 444.55, a P/E/G ratio of 5.80 and a beta of 1.26. The business has a fifty day simple moving average of $96.56 and a 200-day simple moving average of $86.35. The company has a quick ratio of 7.32, a current ratio of 7.44 and a debt-to-equity ratio of 0.96.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Monday, July 29th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.13. Neurocrine Biosciences had a return on equity of 0.46% and a net margin of 2.98%. The business had revenue of $183.58 million during the quarter, compared to analysts’ expectations of $161.79 million. During the same quarter last year, the business posted ($0.07) earnings per share. The business’s revenue for the quarter was up 89.5% on a year-over-year basis. On average, sell-side analysts anticipate that Neurocrine Biosciences will post 0.68 earnings per share for the current year.

In related news, insider Darin Lippoldt sold 6,736 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $100.00, for a total transaction of $673,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin Charles Gorman sold 80,000 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $95.31, for a total value of $7,624,800.00. Following the sale, the chief executive officer now directly owns 468,508 shares in the company, valued at approximately $44,653,497.48. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 181,461 shares of company stock worth $17,157,806. Corporate insiders own 4.30% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of NBIX. Nuveen Asset Management LLC acquired a new stake in Neurocrine Biosciences in the 2nd quarter worth about $64,739,000. Point72 Asset Management L.P. boosted its stake in Neurocrine Biosciences by 189.4% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,124,684 shares of the company’s stock worth $94,957,000 after buying an additional 735,992 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Neurocrine Biosciences by 6.1% in the 2nd quarter. Janus Henderson Group PLC now owns 9,352,240 shares of the company’s stock worth $789,610,000 after buying an additional 540,279 shares during the last quarter. Perceptive Advisors LLC boosted its stake in Neurocrine Biosciences by 7.1% in the 2nd quarter. Perceptive Advisors LLC now owns 4,023,862 shares of the company’s stock worth $339,734,000 after buying an additional 265,200 shares during the last quarter. Finally, Marshall Wace North America L.P. boosted its stake in Neurocrine Biosciences by 83.5% in the 1st quarter. Marshall Wace North America L.P. now owns 580,904 shares of the company’s stock worth $51,178,000 after buying an additional 264,402 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Read More: Do closed-end mutual funds pay dividends?

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.